Cargando…

Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis

BACKGROUND: One of the key pathological hallmarks of Alzheimer disease (AD) is the accumulation of the amyloid-β (Aβ) peptide into amyloid plaques. The apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset AD and has been shown to influence the accumulation of Aβ in the br...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahan, Thomas E., Wang, Chao, Bao, Xin, Choudhury, Ankit, Ulrich, Jason D., Holtzman, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811969/
https://www.ncbi.nlm.nih.gov/pubmed/35109920
http://dx.doi.org/10.1186/s13024-022-00516-0
_version_ 1784644546556067840
author Mahan, Thomas E.
Wang, Chao
Bao, Xin
Choudhury, Ankit
Ulrich, Jason D.
Holtzman, David M.
author_facet Mahan, Thomas E.
Wang, Chao
Bao, Xin
Choudhury, Ankit
Ulrich, Jason D.
Holtzman, David M.
author_sort Mahan, Thomas E.
collection PubMed
description BACKGROUND: One of the key pathological hallmarks of Alzheimer disease (AD) is the accumulation of the amyloid-β (Aβ) peptide into amyloid plaques. The apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset AD and has been shown to influence the accumulation of Aβ in the brain in an isoform-dependent manner. ApoE can be produced by different cell types in the brain, with astrocytes being the largest producer of apoE, although reactive microglia also express high levels of apoE. While studies have shown that altering apoE levels in the brain can influence the development of Aβ plaque pathology, it is not fully known how apoE produced by specific cell types, such as astrocytes, contributes to amyloid pathology. METHODS: We utilized APOE knock-in mice capable of having APOE selectively removed from astrocytes in a tamoxifen-inducible manner and crossed them with the APP/PS1-21 mouse model of amyloidosis. We analyzed the changes to Aβ plaque levels and assessed the impact on cellular responses to Aβ plaques when astrocytic APOE is removed. RESULTS: Tamoxifen administration was capable of strongly reducing apoE levels in the brain by markedly reducing astrocyte apoE, while microglial apoE expression remained. Reduction of astrocytic apoE3 and apoE4 led to a large decrease in Aβ plaque deposition and less compact plaques. While overall Iba1(+) microglia were unchanged in the cortex after reducing astrocyte apoE, the expression of the disease-associated microglial markers Clec7a and apoE were lower around amyloid plaques, indicating decreased microglial activation. Additionally, astrocyte GFAP levels are unchanged around amyloid plaques, but overall GFAP levels are reduced in the cortex of female apoE4 mice after a reduction in astrocytic apoE. Finally, while the amount of neuritic dystrophy around remaining individual plaques was increased with the removal of astrocytic apoE, the overall amount of cortical amyloid-associated neuritic dystrophy was significantly decreased. CONCLUSION: This study reveals an important role of astrocytic apoE3 and apoE4 on the deposition and accumulation of Aβ plaques as well as on certain Aβ-associated downstream effects. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13024-022-00516-0.
format Online
Article
Text
id pubmed-8811969
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88119692022-02-03 Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis Mahan, Thomas E. Wang, Chao Bao, Xin Choudhury, Ankit Ulrich, Jason D. Holtzman, David M. Mol Neurodegener Research Article BACKGROUND: One of the key pathological hallmarks of Alzheimer disease (AD) is the accumulation of the amyloid-β (Aβ) peptide into amyloid plaques. The apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset AD and has been shown to influence the accumulation of Aβ in the brain in an isoform-dependent manner. ApoE can be produced by different cell types in the brain, with astrocytes being the largest producer of apoE, although reactive microglia also express high levels of apoE. While studies have shown that altering apoE levels in the brain can influence the development of Aβ plaque pathology, it is not fully known how apoE produced by specific cell types, such as astrocytes, contributes to amyloid pathology. METHODS: We utilized APOE knock-in mice capable of having APOE selectively removed from astrocytes in a tamoxifen-inducible manner and crossed them with the APP/PS1-21 mouse model of amyloidosis. We analyzed the changes to Aβ plaque levels and assessed the impact on cellular responses to Aβ plaques when astrocytic APOE is removed. RESULTS: Tamoxifen administration was capable of strongly reducing apoE levels in the brain by markedly reducing astrocyte apoE, while microglial apoE expression remained. Reduction of astrocytic apoE3 and apoE4 led to a large decrease in Aβ plaque deposition and less compact plaques. While overall Iba1(+) microglia were unchanged in the cortex after reducing astrocyte apoE, the expression of the disease-associated microglial markers Clec7a and apoE were lower around amyloid plaques, indicating decreased microglial activation. Additionally, astrocyte GFAP levels are unchanged around amyloid plaques, but overall GFAP levels are reduced in the cortex of female apoE4 mice after a reduction in astrocytic apoE. Finally, while the amount of neuritic dystrophy around remaining individual plaques was increased with the removal of astrocytic apoE, the overall amount of cortical amyloid-associated neuritic dystrophy was significantly decreased. CONCLUSION: This study reveals an important role of astrocytic apoE3 and apoE4 on the deposition and accumulation of Aβ plaques as well as on certain Aβ-associated downstream effects. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13024-022-00516-0. BioMed Central 2022-02-02 /pmc/articles/PMC8811969/ /pubmed/35109920 http://dx.doi.org/10.1186/s13024-022-00516-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Mahan, Thomas E.
Wang, Chao
Bao, Xin
Choudhury, Ankit
Ulrich, Jason D.
Holtzman, David M.
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis
title Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis
title_full Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis
title_fullStr Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis
title_full_unstemmed Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis
title_short Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis
title_sort selective reduction of astrocyte apoe3 and apoe4 strongly reduces aβ accumulation and plaque-related pathology in a mouse model of amyloidosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811969/
https://www.ncbi.nlm.nih.gov/pubmed/35109920
http://dx.doi.org/10.1186/s13024-022-00516-0
work_keys_str_mv AT mahanthomase selectivereductionofastrocyteapoe3andapoe4stronglyreducesabaccumulationandplaquerelatedpathologyinamousemodelofamyloidosis
AT wangchao selectivereductionofastrocyteapoe3andapoe4stronglyreducesabaccumulationandplaquerelatedpathologyinamousemodelofamyloidosis
AT baoxin selectivereductionofastrocyteapoe3andapoe4stronglyreducesabaccumulationandplaquerelatedpathologyinamousemodelofamyloidosis
AT choudhuryankit selectivereductionofastrocyteapoe3andapoe4stronglyreducesabaccumulationandplaquerelatedpathologyinamousemodelofamyloidosis
AT ulrichjasond selectivereductionofastrocyteapoe3andapoe4stronglyreducesabaccumulationandplaquerelatedpathologyinamousemodelofamyloidosis
AT holtzmandavidm selectivereductionofastrocyteapoe3andapoe4stronglyreducesabaccumulationandplaquerelatedpathologyinamousemodelofamyloidosis